Fig. 14.1 Possible intraductal and discontinuous peritumoral spread of DCIS These issues warrant thorough preoperative assessment (usually breast MRI). Most DCIS are non-palpable lesions (mostly microcalcifications) so careful preoperative localization…
Fig. 6.1 Axial contrast-enhanced arterial phase MDCT demonstrates dilatation of the distal common bile duct (*) due to isoattenuating adenocarcinoma (arrow) of the pancreatic head. The main pancreatic duct of…
Fig. 5.1 A large HCC in a 75-year-old HCV-positive patient treated by selective internal radiation treatment (SIRT). (a) Angiographic image during SIRT. (b) CT after SIRT. (c) The specimen after…
Fig. 15.1 The da VinciTM robotic system (courtesy of Surgical Intuitive, Inc., Sunnyvale, CA, USA) Instruments EndoWrist instruments are designed to provide surgeons with natural dexterity and a full range…
Fig. 11.1 The four temperaments—(from left to right) choleric, melancholic, sanguine and phlegmatic— on the wall of a house at the corner of Am Dornbusch and Eschersheimer Landstraße in Dornbusch,…
Fig. 9.1 Pancreatic neuroendocrine tumors: stage at diagnosis Histological Features and World Health Organization (WHO) Classification 2010 Neuroendocrine tumors (NETs) are considered to be epithelial neoplasms with neuroendocrine differentiation. However,…
Primary tumor (T) TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ: intra-epithelial or invasion of lamina propria T1 Tumor invades submucosa T2…
Andrea Valeri, Carlo Bergamini, Ferdinando Agresta and Jacopo Martellucci (eds.)What’s New in Surgical OncologyA Guide for Surgeons in Training and Medical/Radiation Oncologists10.1007/978-88-470-5310-6_17 © Springer-Verlag Italia 2013 17. Cancers of Unknown Origin Fabio Cesare Campanile3 , Gian Luca Baiocchi1, Nereo Vettoretto4 and Ferdinando Agresta2 (1)…
Patient number RECIST PFS (months) Survival (months) SLTS (%) Primary (%) Metastates (%) Overall (%) Overall 1 -9 -9 4 -1 SD 10 18+ 2 – – – – –…
Phase II trials N. Design RT dose CR Median F/U 3 yr DFS 3 yr CFS OS RTOG-0529 phase II completed accrual March 2008 63 5FU 1000 mg/m2 days 1–4…
